Luke Pase

Luke Pase is Chief Technology Officer at Anocca AB, where he leads development of advanced platforms for T cell receptor–based therapies. He has been with the company for over a decade, previously serving as Lead Scientist – Molecular Genetics, helping to build its discovery and technology capabilities. His work focuses on advancing proprietary platform technologies and a novel non-viral gene editing process accelerating the development of next-generation TCR-T cell therapies. Earlier in his career, Luke held postdoctoral research positions at the Karlsruhe Institute of Technology, Peter MacCallum Cancer Centre, and Monash University. He completed his PhD at the Walter and Eliza Hall Institute of Medical Research in Melbourne.